Sodium-coupled glucose transport, the SLC5 family, and therapeutically relevant inhibitors: from molecular discovery to clinical application.
Level 5 - mechanism / opinion, no new human data
Narrative review of transporter physiology and pharmacology without systematic search methodology.
PubMed 32767111 · doi:10.1007/s00424-020-02433-x
What was done
This narrative review summarizes the history, molecular genetics, structural biology, and pharmacology of the SLC5 sodium glucose transporter family. The authors describe the physiological roles of SGLT1 in intestinal absorption and SGLT2 in renal proximal tubule glucose reabsorption, alongside the therapeutic development and mechanisms of SGLT2 inhibitors (gliflozins).
What was found
The abstract reports no numerical findings or effect sizes. It qualitatively describes the functional roles of SGLT1 in intestinal sugar uptake and SGLT2 in renal glucose reabsorption, notes the antidiabetic, nephroprotective, and cardioprotective benefits of gliflozins, and highlights emerging findings of SGLT2 expression in pancreatic cancer, prostate cancer, and glioblastoma.
Why it matters
It provides an overarching physiological and pharmacological overview connecting transporter molecular biology to the clinical benefits of SGLT2 inhibitors across metabolic, renal, and cardiovascular diseases.
Limits
As a narrative review, it lacks a systematic literature search, pre-specified inclusion criteria, and formal risk-of-bias evaluation. No quantitative primary data are provided in the abstract, and proposed applications such as oncology targeting reflect preliminary exploratory findings rather than established clinical efficacy.
Cited by
- supports The glucose transporter in the intestinal tract is sodium-mediated, allowing glucose with salt to be absorbed faster than glucose alone.